Anika Therapeutics (NASDAQ:ANIK) issued an update on its FY 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.
ANIK stock traded down $0.67 during trading on Thursday, reaching $44.76. The company’s stock had a trading volume of 165,320 shares, compared to its average volume of 129,933. Anika Therapeutics has a 1 year low of $31.55 and a 1 year high of $48.37. The firm has a market cap of $644.14 million, a P/E ratio of -23.68, a P/E/G ratio of 24.26 and a beta of 1.21. The company has a fifty day moving average price of $42.54.
Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings results on Wednesday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative return on equity of 0.98% and a negative net margin of 20.83%. The business had revenue of $34.29 million during the quarter, compared to analyst estimates of $32.39 million. Analysts anticipate that Anika Therapeutics will post 0.19 earnings per share for the current fiscal year.
In other news, Director Raymond J. Land sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 12th. The stock was sold at an average price of $42.60, for a total transaction of $85,200.00. Following the completion of the transaction, the director now owns 7,953 shares in the company, valued at $338,797.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.09% of the company’s stock.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.
Featured Article: How is a buy-side analyst different from a sell-side analyst?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.